Vericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences
Vericel Corporation (NASDAQ:VCEL) announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) announced its participation in two upcoming investor conferences. On September 13, 2022, at 8:00 a.m. ET, President and CEO Nick Colangelo and CFO Joe Mara will engage in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference. The following day, September 14, 2022, Joe Mara will present at the H.C. Wainwright 24th Annual Global Investment Conference at 9:00 a.m. ET. Webcasts of both events will be accessible via the Investor Relations section of Vericel's website.
Details
News Market Reaction – VCEL
The recorded move for VCEL in the trading session of this news was -0.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Morgan Stanley and H.C. Wainwright investor conferences.
Nick Colangelo, President and CEO, and Joe Mara, CFO will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference at 8:00 a.m. ET on Tuesday, September 13, 2022. On Wednesday, September 14, 2022, Mr. Mara will engage in a fireside chat at 9:00 a.m. ET at the H.C. Wainwright 24th Annual Global Investment Conference.
Webcasts of both presentations will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.
About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2022 Vericel Corporation. All rights reserved.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
Media Contact:
Julie Downs
media@vcel.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.